Cargando…
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
Fifty percent of cutaneous melanomas are driven by activated BRAF (V600E), but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms of intrinsic and adaptive resistance and devel...
Autores principales: | Capaldo, Brian J., Roller, Devin, Axelrod, Mark J., Koeppel, Alex F., Petricoin, Emanuel F., Slingluff, Craig L., Weber, Michael J., Mackey, Aaron J., Gioeli, Daniel, Bekiranov, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583389/ https://www.ncbi.nlm.nih.gov/pubmed/26405815 http://dx.doi.org/10.1371/journal.pone.0138210 |
Ejemplares similares
-
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015) -
IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK
por: Lehman, Christine E., et al.
Publicado: (2021) -
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
por: Bollag, Gideon, et al.
Publicado: (2010) -
Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020) -
Systems analysis of barrier molecule and ARNT-related gene expression regulation in melanoma
por: Leick, Katie M., et al.
Publicado: (2019)